Publication Name	World Journal of Gastroenterology
Manuscript ID	114558
Country	China

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Scutellaria baicalensis Georgi as a potential therapeutic drug intervention in ulcerative colitis: Mechanisms of action and clinical trials
Manuscript Source	Unsolicited Manuscript
All Author List	Yi Ding, Chu-Ye Wang, Ya-Ting Pan, Yu-Jia Wang, Ai-Guang Zhao and Hong-Zhu Wen
Funding Agency and Grant Number	Funding Agency Grant Number National Natural Science Foundation of China 82374200 Construction of Traditional Chinese Medicine Inheritance and Innovation Development Demonstration Pilot Projects in Pudong New Area - High-Level Research-Oriented Traditional Chinese Medicine Hospital Construction YC-2023-0901
Corresponding Author	Hong-Zhu Wen, Department of Gastroenterology, Longhua Hospital Shanghai University of Traditional Chinese Medicine, No. 725 Wanping Road, Shanghai 200032, China. ellawhz@sina.com
Key Words	Ulcerative colitis; Scutellaria baicalensis Georgi; Mechanism of action; Clinical trials; Traditional Chinese medicine therapy
Core Tip	As a traditional Chinese medicine, Scutellaria baicalensis Georgi (HQ) plays a crucial role in the treatment of ulcerative colitis (UC) since it contains multiple active components, such as baicalein, wogonin, baicalin, wogonoside and polysaccharides. HQ exerts therapeutic efficacy in UC through multiple mechanisms, including modulation of pro- and anti-inflammatory cytokine expression, regulation of immune cell function, protection of the intestinal barrier, and exertion of antioxidant and anti-apoptotic activities, as well as modulation of the gut microbiota. Clinically, HQ-based formulations, either used alone or in combination with conventional Western medications, have demonstrated favorable outcomes in UC management, such as reducing adverse drug reactions, enhancing therapeutic efficacy, and lowering recurrence rates.
Citation	Ding Y, Wang CY, Pan YT, Wang YJ, Zhao AG, Wen HZ. Scutellaria baicalensis Georgi as a potential therapeutic drug intervention in ulcerative colitis: Mechanisms of action and clinical trials. World J Gastroenterol 2025; In press

Received	2025-09-23 06:51
Peer-Review Started	2025-09-23 06:53
To Make the First Decision
Return for Revision	2025-10-18 03:16
Revised	2025-10-30 22:18
Second Decision	2025-11-19 02:35
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2025-11-19 09:51
Articles in Press	2025-11-19 09:51
Publication Fee Transferred	2025-11-03 08:21
Edit the Manuscript by Language Editor
Typeset the Manuscript

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com